# BEXLUTRY (Lutetium Lu 177 dotatate) by Curium US LLC: new human prescription drug listing

**Launch Signal Score:** 80/100

| Field | Value |
|---|---|
| Product | BEXLUTRY |
| Generic name | Lutetium Lu 177 dotatate |
| NDC | 69945-177 |
| Labeler | Curium US LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Approval pathway | NDA |
| Application number | NDA218525 |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Active ingredients | LUTETIUM OXODOTREOTIDE LU-177 10 mCi/mL |
| Marketing start | 2026-09-14 |
| Package configurations | 1 |

## Why this score
- Prescription or biologic product.
- Brand or biologic launch.
- Injectable: hospital and 503B relevance.

Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=69945-177). Last refreshed: 2026-11-04T18:12:05.743Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.